Dr. Goodenowe Dietary Therapeutics LLC announces FDA-governed development pathway for nutrient-based compounds
Plasmalogen precursors for Alzheimer’s are named as first program candidate TEMECULA, CA, UNITED STATES, February 20, 2026 /EINPresswire.com/ -- Dr. Goodenowe Dietary Therapeutics LLC, a U.S.-based company formed to advance selected dietary nutrients …